Amalgamated Bank Sells 4,598 Shares of Illumina, Inc. (NASDAQ:ILMN)

Amalgamated Bank lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 5.7% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 75,924 shares of the life sciences company’s stock after selling 4,598 shares during the period. Amalgamated Bank’s holdings in Illumina were worth $9,901,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. First Trust Direct Indexing L.P. acquired a new stake in shares of Illumina during the 1st quarter worth approximately $229,000. Norden Group LLC acquired a new position in shares of Illumina in the 1st quarter valued at $584,000. Private Advisor Group LLC raised its stake in shares of Illumina by 4.8% in the 1st quarter. Private Advisor Group LLC now owns 4,955 shares of the life sciences company’s stock valued at $679,000 after buying an additional 226 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Illumina by 41.5% during the 1st quarter. Janney Montgomery Scott LLC now owns 3,070 shares of the life sciences company’s stock worth $422,000 after acquiring an additional 900 shares during the period. Finally, Nordea Investment Management AB boosted its position in shares of Illumina by 5.8% during the 1st quarter. Nordea Investment Management AB now owns 14,382 shares of the life sciences company’s stock valued at $1,981,000 after acquiring an additional 784 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Up 1.0 %

Illumina stock opened at $154.96 on Wednesday. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a 50 day moving average price of $136.87 and a two-hundred day moving average price of $122.92. The firm has a market cap of $24.69 billion, a price-to-earnings ratio of -15.56 and a beta of 1.13.

Illumina (NASDAQ:ILMN) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. Illumina’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.33 earnings per share. Equities analysts predict that Illumina, Inc. will post 3.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Piper Sandler decreased their price target on Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. StockNews.com started coverage on shares of Illumina in a report on Thursday, August 29th. They issued a “buy” rating for the company. Daiwa Capital Markets raised Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the company from $120.00 to $154.00 in a research note on Friday, August 16th. Scotiabank cut their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Finally, Robert W. Baird raised their target price on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Illumina presently has a consensus rating of “Moderate Buy” and an average target price of $161.50.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.